

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>	
			Application Number	09/844,864
			Filing Date	April 27, 2001
			First Named Inventor	Martin M. Matzuk
			Art Unit	1645
			Examiner Name	DIANE RUSSELE
Attorney Docket Number	HO-P01925US2			
Sheet	1	of	4	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
CW	AA*	5801016-	09-01-1998	Morioka et al.	
CW	AB*	5547854-	08-20-1996	Donahoe et al.	
CW	AC*	5563059-	10-08-1996	Alak et al.	
CW	AD*	5661126-	08-26-1997	Donahoe et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
CW	BA*	-WO98/40483-	09-17-1998	Human Genome Sciences, Inc.	

Examiner Signature	<i>Cynthia J. Lohman</i>	Date Considered	2/6/03
--------------------	--------------------------	-----------------	--------

*References found in related application 09/830,810*

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See attached Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

RECEIVED

SEP 26 2002

TECH CENTER 1600/2900



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/844,864		
		Filing Date	April 27, 2001		
		First Named Inventor	Martin M. Matzuk		
		Group Art Unit	1645		
		Examiner Name	DIANE RUSSELL		
Sheet	2	of	4	Attorney Docket Number	HO-P01925US2

RECEIVED


SEP 26 2002

TECH CENTER 1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
CW	CA*	Elvin, Julia A., et al.; Paracrine Actions of Growth Differentiation Factor-9 in the Mammalian Ovary; Molecular Endocrinology; Vol. 13, No. 6; 1999	
CW	CB*	Elvin, Julia A., et al.; Molecular Characterization of the Follicle Defects in the Growth Differentiation Factor 9-Deficient Ovary; Molecular Endocrinology; Vol. 13, No. 6; 1999	
CW	CC*	Matzuk, Martin M., et al.; Transgenic Models to Study the Roles of Inhibins and Activins in Reproduction, Oncogenesis, and Development; Recent Progress in Hormone Research; Vol. 51	
CW	CD*	Ohsumi, Keita, et al.; Characterization of the Ooplasmic Factor Inducing Decondensation of and Protamine Removal from Toad Sperm Nuclei: Involvement of Nucleoplasmin; Developmental Biology; Vol. 148; 1991	
CW	CE*	Philpott, Anna, et al.; Nucleoplasmin Remodels Sperm Chromatin in Xenopus Egg Extracts; Cell; Vol. 69; 1992	
CW	CF*	Matzuk, Martin M., et al.; Different phenotypes for mice deficient in either activins or activin receptor type II; Nature; Vol. 374; 1995	
CW	CG*	Dong, Jinwen, et al.; Growth differentiation factor-9 is required during early ovarian folliculogenesis; Nature; Vol. 383; 1996	
CW	CH*	McGrath, Sharon A., et al.; Oocyte-Specific Expression of Growth/Differentiation Factor-9; Molecular Endocrinology; Vol. 9, No. 1; 1995	
CW	CI*	Kumar, T. Rajendra, et al.; Follicle stimulating hormone is required for ovarian follicle maturation but not male fertility; Nature Genetics; Vol. 15; 1997	
CW	CJ*	Perreault, Sally D.; Chromatin remodeling in mammalian zygotes; Mutation Research; Vol. 296; 1992	
CW	CK*	Krohne, Georg, et al.; Immunological identification and localization of the predominant nuclear protein of the amphibian oocyte nucleus; Proc. Natl. Acad. Sci. USA; Vol. 77, No. 2; 1980	
CW	CL*	Matzuk, Martin M., et al.; a-Inhibin is a tumour-suppressor gene with gonadal specificity in mice; Nature; Vol. 360; 1992	
CW	CM*	Elvin, Julia A., et al.; Growth differentiation factor-9 stimulates progesterone synthesis in granulosa cells via a prostaglandin E2/EP2 receptor pathway; PNAS; Vol. 97, No. 18; 2000	
CW	CN*	MacArthur, Craig A., et al.; Npm3: A Novel, Widely Expressed Gene Encoding a Protein Related to the Molecular Chaperones Nucleoplasmin and Nucleophosmin; Genomics; Vol. 42; 1997	
CW	CO*	Mills, A. D., et al.; An Acidic Protein Which Assembles Nucleosomes in Vitro is the Most Abundant Protein in Xenopus Oocyte Nuclei; J. Mol. Biol.; Vol. 139; 1980	
CW	CP*	Dingwall, Colin, et al.; Nucleoplasmin cDNA sequence reveals polyglutamic acid tracts and a cluster of sequences homologous to putative nuclear localization signals; The EMBO Journal; Vol. 6, No. 1; 1987	
CW	CQ*	McLay, David W., et al.; The Ability to Organize Sperm DNA into Functional Chromatin Is Acquired during Meiotic Maturation in Murine Oocytes; Developmental Biology; Vol. 186; 1997	
CW	CR*	Carabatsos, Mary Jo, et al.; Characterization of Oocyte and Follicle Development in Growth Differentiation Factor-9-Deficient Mice; Developmental Biology; Vol. 204; 1998	
CW	CS*	Philpott, Anna, et al.; Sperm Decondensation in Xenopus Egg Cytoplasm Is Mediated by Nucleoplasmin; Cell; Vol. 65; 1991	
CW	CT*	Burglin, Thomas R., et al.; Cloning of nucleoplasmin from Xenopus laevis oocytes and analysis of its developmental expression; Genes & Development; Vol. 1; 1987	

Examiner Signature	Cynthia Wilkie	Date Considered	2/6/03
--------------------	----------------	-----------------	--------

References found in Related Application 09/830,810



PTO/SB/08B (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<div>Substitute for form 1449B/PTO</div> <div><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></div> <div>(use as many sheets as necessary)</div>				<b>Complete if Known</b>	
				Application Number	09/844,864
				Filing Date	April 27, 2001
				First Named Inventor	Martin M. Matzuk
				Group Art Unit	1645
				Examiner Name	DIANE RUSSELE
Sheet	3	of	4	Attorney Docket Number	HO-P01925US2

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

RECEIVED

SEP 26 2002

TECH CENTER 1600/2900